Loading...

AIXC AIXCRYPTO HOLDINGS INC Management Changes 8-K Filing

XCRY

XC

AIXCRYPTO HOLDINGS INC

(AIXC)

2024 8-K

Investment Agreement Update

Financial Results Announced

Business Highlights Announced

Advisor Agreement Signed

Consulting Agreement Entered

Annual Meeting Results

Accountant Change

Nasdaq Compliance Update

Rebranding Announcement

Management Changes

Name Change Announcement

Management Changes

Private Placement Offering

Board Appointment

Private Placement Offering

Debt Amendment Update

Nasdaq Compliance Update

Loan Amendment Update

Voluntary Delisting

Equity Offerings

Notification of Delisting

Forced Delisting

Funding Announcement

Stock Modification

Management Changes

Board Appointment

Stock Split Announcement

Annual Meeting Results

Nasdaq Compliance

Management Changes

Management Changes

Earnings Report

Investment in Marizyme, Inc.

Change in Auditor

Material Definitive Agreement

Agreement and Board Changes

Delisting Notice

Convertible Debenture and C...

Termination of License and ...

Securities Purchase Agreement

License Agreement with Pan-...

Amendment to Securities Pur...

Clinical Trial Update

Regulation FD Disclosure

Financial Results Announcement

Reinstatement of Salaries

FDA Clearance for QN-302 IN...

Stock Purchase Agreement

Resignation of Amy Broidrick

Resignation of Officer

Investor Conferences

Management Changes

FDA Orphan Drug Designation...

External Links:

Qualigen Therapeutics announced the immediate resignations of CEO Michael Poirier and CFO Christopher Lotz due to disagreements about the company's direction, and appointed Kevin Richardson II as Interim CEO and CFO, with a consulting fee of $4,500 per week.

AI Assistant

AIXCRYPTO HOLDINGS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.